Eli Lilly's stock surged to new 52-week highs after promising Phase 3 data for its obesity drug retatrutide, which could become a first-line treatment. Despite some early-year concerns over pricing pressures and competition, the company reported strong Q1 earnings with a 25.9% EPS surprise and raised its full-year revenue guidance. Analysts see potential for the stock to reach $1,500 within a year, driven by continued drug success, market share gains, and possible multiple expansion. Risks include regulatory and pricing challenges, but overall growth prospects remain strong.
The investor highlights NVIDIA's massive revenue growth and cash flow, boosted by AI demand and strong capital returns. Eli Lilly impresses with high revenue growth driven by key drugs like Mounjaro and Foundayo, despite pricing pressures. Johnson & ...
Ahead of its mega-IPO, SpaceX revealed healthcare ambitions in its SEC filing, highlighting Starlink's role in improving remote healthcare access in underserved areas. The company also envisions manufacturing pharmaceuticals in orbit, leveraging micr...
The FDA has approved a new dosing regimen for EBGLYSS (lebrikizumab-lbkz), allowing maintenance injections every eight weeks for adults and children over 12 with moderate-to-severe atopic dermatitis. This offers patients a treatment option with as fe...
Despite geopolitical tensions and inflation concerns in 2026, some large-cap companies like Nvidia and Eli Lilly have posted impressive earnings growth. Investors seeking growth exposure in uncertain markets might consider a concentrated approach, fo...
Eli Lilly's stock surged 54% in nine months, driven by a 56% year-over-year revenue growth and a 47% operating margin, reflecting a fundamental revaluation rather than a simple rebound. The company’s incretin franchise, including Mounjaro and Zepboun...
